Previous 10 | Next 10 |
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Company management will host a conference call and webcast on Friday, July 31, 2020 at 8:00 a.m. EDT to provide an Outside ...
Are These On Your List Of Penny Stocks Right Now? Putting together a good list of penny stocks doesn’t take a whole lot of time. The research certainly can though. Depending on your goals, time frame, and risk tolerance, you can design plenty of lists to fit your strategy. One place t...
The following slide deck was published by Sesen Bio, Inc. in conjunction with this Read more ...
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020. Event ...
Sesen Bio, Inc. (SESN) Q1 2020 Results Conference Call May 11, 2020 08:00 AM ET Company Participants Erin Clark - Vice President of Investor Relations Dr. Thomas Cannell - President and Chief Executive Officer Dr. Chad Myskiw - Strategic Planning, CMC Monica Forbes - Chief Fina...
The following slide deck was published by Sesen Bio, Inc. in conjunction with their 2020 Q1 earnings Read more ...
Sesen Bio (NASDAQ: SESN ): Q1 GAAP EPS of $0.31 beats by $0.40 . More news on: Sesen Bio, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Manufacturing and release testing of the Fujifilm pre-PPQ batch completed successfully Positive Interactions with EMA on Regulatory Pathway for Vicinium ® in Europe Market research conducted in 1Q 2020 supports Urologists prefer Vicinium to Keytruda ® Sesen Bio...
No additional clinical trials were requested by the CHMP for submission of Vicinium marketing authorization application Anticipated submission of marketing authorization application in early 2021 Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing target...
Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Company management will host a conference call and webcast on Monday, May 11, 2020 at 8:00 a.m. ET to review operatin...
News, Short Squeeze, Breakout and More Instantly...
Sesen Bio Inc. Company Name:
SESN Stock Symbol:
NASDAQ Market:
Declares Special Dividend in the Aggregate of $75 Million Approximately 88% Voted in Favor of the Merger at the Special Meeting Merger on Track to Close on March 7, 2023 Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today anno...
Sesen Bio Board Believes the Pending Merger with Carisma is the Most Value-Maximizing Option for Stockholders Reiterates Support from Several of Sesen Bio’s Largest Stockholders and Two Leading Independent Proxy Advisors Sesen Bio Board Unanimously Recommends All St...
Positive Recommendations Underscore that Carisma Merger Maximizes Value for Sesen Bio Stockholders Sesen Bio Board Unanimously Recommends All Stockholders to Follow ISS and Glass Lewis’s Recommendations to Vote “FOR” Value Maximizing Merger on WHITE ...